Boston, MA, United States of America

Wenjun Xiong

This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Harvard College. Active years: 2021-2024.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Wenjun Xiong

Introduction

Wenjun Xiong is a notable inventor based in Boston, MA. He has made significant contributions to the field of oxidative stress research. With a total of 2 patents, his work focuses on innovative methods for treating and preventing disorders associated with oxidative stress.

Latest Patents

Wenjun Xiong's latest patents include methods and compositions for inhibiting oxidative stress. The present invention is directed to methods for the treatment or prevention of oxidative stress in a cell, such as a photoreceptor cell. It also addresses the treatment and prevention of disorders associated with oxidative stress by administering an agent, such as a nucleic acid molecule, which increases the expression and/or activity of an antioxidant defense protein.

Career Highlights

Wenjun Xiong is affiliated with Harvard College, where he continues to advance his research and innovations. His work has garnered attention for its potential applications in medical science and therapeutic interventions.

Collaborations

Wenjun Xiong collaborates with Constance L Cepko, a fellow researcher in the field. Their partnership enhances the scope and impact of their research endeavors.

Conclusion

Wenjun Xiong's contributions to the field of oxidative stress research highlight his innovative spirit and dedication to improving health outcomes. His patents reflect a commitment to advancing scientific knowledge and developing effective treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…